What is this medicine used for?
FDA-approved uses
- Acute bipolar mania; manic or mixed episodes with ER — Adults. Product-specific acute evidence; maintenance requires separate reassessment.Depakote delayed-release tablets; Depakote ER extended-release tablets.
- Specified seizure disorders — Adults and selected pediatric populations according to product and seizure type. Consult exact age and seizure indication.Depakote delayed-release tablets; Depakote ER extended-release tablets; Valproic acid oral capsules.
- Migraine prevention — Adults meeting reproductive-safety restrictions. Not acute migraine treatment.Depakote delayed-release tablets; Depakote ER extended-release tablets.
Other uses (off-label)
Off-label means a medicine is prescribed for a use, age group or form that is not included in its FDA approval.
- Bipolar treatment with valproic acid capsules — Selected patients under clinician supervision. The selected acid-capsule label is for epilepsy; bipolar use is off-label.Valproic acid oral capsules.
What should I expect?
The expected benefit depends on whether the exact product is treating mania, seizures or preventing migraine. Benefit and side effects are followed while the clinician adjusts treatment; sedation can occur before useful improvement.
Follow-up combines symptoms with blood tests when needed. A level in the laboratory’s expected range does not replace checking how you feel or investigating possible toxicity.
How do I take it safely?
Use the prescribed preparation and schedule; delayed-release, extended-release and valproic acid products are not automatically interchangeable. Swallow the covered tablets and acid capsules whole. Food may help stomach upset. Do not use another product’s dose or instructions.
Liver tests, blood counts and platelet or clotting checks are needed before and during treatment, with particular liver monitoring during the first six months. Drug levels may help with changes or suspected toxicity. New confusion or vomiting may need an ammonia test even if liver tests are normal.
Discuss all medicines, especially lamotrigine, topiramate, aspirin, carbapenem antibiotics, methotrexate, estrogen-containing contraception, cannabidiol and sedatives. Valproate is contraindicated in significant liver disease, urea-cycle disorders and specified mitochondrial disorders. Very young children and frail older adults need particular caution.
Pregnancy can involve major birth defects and developmental harm. Migraine prevention is contraindicated in pregnancy and without effective contraception in people who can become pregnant; epilepsy or bipolar use in pregnancy is restricted to situations where alternatives are inadequate. Discuss pregnancy planning, contraception and breastfeeding promptly.
Do not stop abruptly, particularly with epilepsy. Take a missed dose when remembered unless the next is near, then skip it. Never double; contact the team about repeated missed doses or pregnancy.
Do not use this product after a known allergy to its active medicine or ingredients; tell the pharmacist about previous medication reactions.
What side effects should I know about?
- Gastrointestinal upset, sedation, tremor, weight gain and hair loss.
Tell your prescriber about effects that are persistent, troublesome, or interfere with daily life.
Looking for more detailed information?
The official medicine information lists more side effects, safety advice and product instructions.
- View FDA Prescribing Information (PDF) (opens in a new tab)DEPAKOTE- divalproex sodium tablet, delayed release
- View FDA Prescribing Information (PDF) (opens in a new tab)DEPAKOTE ER- divalproex sodium tablet, extended release
- View FDA Prescribing Information (PDF) (opens in a new tab)VALPROIC- valproic acid capsule, liquid filled
Which warning signs need help?
- Boxed warningsFDA boxed warningAn FDA boxed warning is a prominently displayed warning in US prescribing information about especially serious risks, which may include death or serious injury. It is sometimes called a black-box warning.It highlights information that needs particular attention when deciding whether and how to use a medicine. A boxed warning does not mean the medicine is banned or that everyone will experience the harm. Read the medicine-specific warning and discuss it with your prescriber. cover potentially fatal liver injury and pancreatitis, and serious fetal or developmental harm during pregnancy. The first six months, children under 2 and specified mitochondrial disorders carry particular liver risk.
- Severe persistent abdominal pain with vomiting needs urgent assessment for pancreatitis. Jaundice, marked weakness, poor appetite, facial swelling, unusual bleeding or pronounced confusion also needs prompt urgent assessment. High ammonia can cause illness even with normal liver tests.
- Blistering rash, mouth sores or fever with swollen glands can indicate a dangerous skin or multiorgan reaction. Seek emergency care for a seizure, collapse, serious breathing difficulty, facial or throat swelling, or suspected overdose. Contact the prescriber promptly for new suicidal thoughts, worsening depression or unusual behavior. Use emergency care if there is immediate danger or the person cannot stay safe.
What else should I know to stay safe?
- Do not use with significant liver disease, urea-cycle disorders, specified mitochondrial disorders or product allergy. Check liver function, blood counts and clotting before and during treatment, with close liver monitoring during the first six months; drug levels or ammonia tests may be needed.
- Pregnancy planning and reliable contraception are essential. Migraine prevention is contraindicated during pregnancy or without effective contraception in someone who can become pregnant; epilepsy or bipolar use during pregnancy is restricted to situations where alternatives are inadequate. Discuss breastfeeding.
- Check interactions, particularly lamotrigine, topiramate, aspirin, carbapenem antibiotics, methotrexate, estrogen-containing contraception, cannabidiol and sedatives. Release forms are not automatically interchangeable. Do not stop abruptly, especially with epilepsy; young children and frail older adults need particular care. Pediatric seizure approvals depend on the exact product; Depakote ER seizure uses begin at age 10. Pediatric studies did not establish effectiveness for mania or migraine prevention. Methotrexate or estrogen-containing contraception can lower valproate levels; cannabidiol can increase abnormal liver-test risk. Discuss starts and stops so blood levels, symptoms and liver tests can be monitored.
Urgent help and crisis support · Emergency & Crisis Resources (US)
What can help day to day?
- Delayed-release and extended-release products may require different total daily amounts. A switch needs the prescriber’s plan, even when the tablets have similar names.
- Pregnancy planning is central to this medicine, not an optional extra. Risks and acceptable alternatives differ between migraine prevention, epilepsy and bipolar treatment.
How does it work?
Valproate changes several processes involved in nerve-cell activity. One proposed effect is to increase the availability of GABA, a chemical messenger that usually makes nerve cells less likely to fire. This may contribute to its antiseizure effects, but the full explanation for its benefits, including its effects on mood, is still uncertain.
How was this medicine developed?
Depakote delayed-release tablets were approved in 1983 and Depakote ER in 2000. Different release systems changed administration, while major pregnancy, liver and pancreatic risks remained important across valproate products.
How do I say the name?
Valproate preparations: Valproate: val-pro-ate; valproic acid: val-PROE-ik acid. Capital letters show the stressed syllable.
Medicine forms and official information
Match the full name, release type and route on your prescription. Different formulations need their own prescribing instructions; do not switch or substitute them yourself.
Choose a formulation
Depakote ER
Divalproex sodium extended-release tablets
See this product’s official label for its prescribing instructions.
Official product information: Depakote ER — U.S. official label (DailyMed)
Divalproex delayed-release tablets
Divided dosing; not equivalent to ER at the same daily amount.
Valproic acid capsules
Selected epilepsy-labeled capsules; bipolar use off-label.
Other valproate preparations
IV, sprinkle and liquid instructions require their own label review.
Sources and References
Sources support the U.S. products described here. Product instructions can differ; use the information supplied with your own medicine.
- Valproate preparations: current prescribing information — mechanism explanation
Scope: Mechanism explanation only. Source sections checked: 12.1 Mechanism of Action; 12.2 Pharmacodynamics; 12.3 Pharmacokinetics..
- Valproate preparations: FDA approval history
- Valproate preparations: patient medicine information
- Depakote ER prescribing information
- Valproic acid capsules prescribing information
- Depakote ER FDA approval history
- Information leaflet about medicine reviews for women and people taking valproate
- Valproate preparations: FDA prescribing information
- Depakote: Package Insert / Prescribing Information / MOA
- DailyMed - VALPROIC ACID capsule, liquid filled
- Lamotrigine: prescribing information
- Valproate preparations: verified neutral parent, PubChem CID 3121
- ISMP List of Confused Drug Names
- ISMP List of High-Alert Medications in Community/Ambulatory Care Settings
- Depakote ER
- Frequently Asked Questions about Labeling for Prescription Medicines | FDA
Giving medicine safely to children: family guide (PDF, 3 pages)

